Review exclusive coverage of Advancement in Oncology: Today’s Data for Tomorrow’s Practice, held at theWit Chicago on June 1, 2024. This first event co-hosted by The Oncology Brothers and Mashup Media highlighted breakthrough data on genitourinary cancers, insights from an esteemed panel of experts, and commentary on research presented at ASCO 2024.
The Oncology Brothers
Drs. Rohit Gosain and Rahul Gosain, the Oncology Brothers, are board certified in internal medicine, hematology, and oncology. They work in the community setting as generalists, and their mission is to bridge the gap between the community and academia by providing key insights and succinct conference updates, discussing practice-changing data, and reiterating the standard of care.
Advertisement
Dr. Tawagi considers how "favorable" and "very favorable" risk alters her approach to patient management for aRCC.
Dr. Tawagi opines on whether the high rates of crossover in the PSMAfore control arm limit the applicability of the results.
Dr. Tawagi provides an update as to when SG or chemotherapy should be preferred for patients who do not respond to EV/pembro.
Dr. Tawagi describes how she is using ctDNA in her practice in the EV/pembro setting, and how frequently she is ordering it.
Dr. Tawagi explains the treatment options available for patients with metastatic bladder cancer who already have neuropathy.
Dr. Tawagi shares how she counsels patients with metastatic UC, including whether she always recommends EV/pembro.
The discussion focused on advanced and metastatic stages of RCC, shedding light on current practices in clinics.
Dr. Karine Tawagi focused this part of her discussion on 177Lu-PSMA-617 and the PSMAfore trial updates.
How can clinical tools like circulating tumor DNA inform bladder cancer treatment adjustments and transitions?
Dr. Tawagi delved into the latest developments in bladder cancer treatment, beginning with the presentation of EV-302.
The Oncology Brothers chat with Dr. Wallis on PARP inhibitors as well as neoadjuvant IO and EV for bladder cancer.
Petros Grivas, MD, PhD, highlights the practice-changing studies that have come out of the ASCO GU 2023 Symposium.
Neeraj Agarwal, MD, shares the standard-of-care treatment algorithms for localized prostate cancer, CSPC, and CRPC.
Elizabeth Plimack, MD, MS, Deputy Director, Fox Chase Cancer Center, shares her approach to treating renal cell cancer.
Andrea Apolo, MD, Chief of Bladder Cancer - Genitourinary Malignancy at the NCI, discusses bladder cancer treatment.
Dr. Rahul Gosain’s Disclosures
Advisory Board: AstraZeneca
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.